Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE and PRIME Oncology have partnered to present to you information from the prIME Oncology satellite symposium held in conjunction with the 2018...
GRACE and PRIME Oncology have partnered to present to you information from the prIME Oncology satellite symposium held in conjunction with the 2018...
GRACE and PRIME Oncology have partnered to present to you information from the prIME Oncology satellite symposium held in conjunction with the 2018...
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.